Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
4.910
-0.100 (-2.00%)
At close: Jan 21, 2025, 4:00 PM
4.930
+0.020 (0.41%)
After-hours: Jan 21, 2025, 6:36 PM EST
Ardelyx Revenue
Ardelyx had revenue of $98.24M in the quarter ending September 30, 2024, with 74.21% growth. This brings the company's revenue in the last twelve months to $251.85M, up 87.57% year-over-year. In the year 2023, Ardelyx had annual revenue of $124.46M with 138.61% growth.
Revenue (ttm)
$251.85M
Revenue Growth
+87.57%
P/S Ratio
4.56
Revenue / Employee
$943,255
Employees
267
Market Cap
1.16B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 124.46M | 72.30M | 138.61% |
Dec 31, 2022 | 52.16M | 42.06M | 416.57% |
Dec 31, 2021 | 10.10M | 2.53M | 33.36% |
Dec 31, 2020 | 7.57M | 2.29M | 43.36% |
Dec 31, 2019 | 5.28M | 2.67M | 102.57% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
ARDX News
- 8 days ago - Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities - GlobeNewsWire
- 15 days ago - Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It - Seeking Alpha
- 2 months ago - Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability - Seeking Alpha
- 2 months ago - Ardelyx Responds to District Court Decision Granting Motion to Dismiss - GlobeNewsWire
- 2 months ago - Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference - GlobeNewsWire
- 2 months ago - Ardelyx, Inc. (ARDX) Q3 2024 Earnings Call Transcript - Seeking Alpha